Patheon to feature SoluPath at CPhI Japan conference

Published: 6-Jul-2011
Research & Development

SoluPath screening includes non-GMP formulation utilising five different drug delivery modalities


Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will feature its paradigm changing SoluPath service offering at the CPhI Conference, which runs from 13 – 15 July 2011 in Osaka, Japan. This fixed price service offering is designed to improve bioavailability of compounds with poor solubility by testing, in parallel, multiple formulations.

SoluPath screening includes non-GMP formulation utilising five different drug delivery modalities: micronisation, nanoparticles, lipid-based solutions, co-solvent solutions SMEDDS/SEDDS, and spray drying. By screening multiple cutting edge technologies in parallel, SoluPath delivers rapid results and identifies the best drug delivery solution to increase bioavailability in human studies.

Patheon’s Dr. Kenji Yamada will talk about the SoluPath process during his presentation on 13 July at 11:30 a.m. in Room A. Patheon representatives will also be available to discuss the company’s new service offering at Booth F14 through the duration of the conference.

  • Companies:
  • Patheon
  • CPhI Japan
See more

You may also like

Manufacturing

Japan produces highest quality APIs, CPhI data says

Read more
Several COVID vaccines are approaching commercial launch in Japan, coinciding with an ongoing biosimilars boom

Trending Articles

  1. SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
  2. SeaBeLife awarded over €1.5 million in i-Nov innovation competition Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
  3. Kynos Therapeutics’ KMO inhibitor demonstrates safety and tolerability in Phase I study The lead drug candidate, KNS366, demonstrated its safety and tolerability in healthy adult participants in a Phase I trial
  4. Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Japan produces highest quality APIs, CPhI data says

Several COVID vaccines are approaching commercial launch in Japan, coinciding with an ongoing biosimilars boom
Research & Development

CPhI Japan: Internationalisation reaches new heights

Innovation in the country, driven by structural and and regulatory changes, has promoted both inbound and outbound collaboration
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend
Regulatory

Fortress Biotech subsidiary Caelum Biosciences enters biopharmaceutical manufacturing agreement with Patheon

Agreement will support Phase II/III studies of Caelum's CAEL-101 in AL amyloidosis
Manufacturing

Thermo Fisher Scientific to acquire leading CDMO, Patheon

The transaction represents a purchase price of approximately $7.2bn
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Now is the time to outsource the management of outsourcing

More than ever before, specialist expertise is being called upon by the pharma industry – from strategy, supply chain and regulatory boutiques through to one-stop CDMOs that provide the whole spectrum of API development to final product production. Susan Birks talked to Patheon about the trends
Manufacturing

Patheon agrees biologics deal with Inhibrx

Initial development work will focus on establishing platform processes for Inhibrx’s cell lines
Subscribe now